CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
RIST4721 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03988335
NCT03988335Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis

Aristea Therapeutics, Inc.·interventional·Posted Jun 17, 2019·Updated Apr 5, 2022

In Brief

A Phase 2 clinical trial evaluating RIST4721 and Placebo for Palmoplantar Pustulosis. Completed, enrolled 35 participants across 17 sites in 2 countries.

Detailed Summary

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPalmoplantar Pustulosis
CountriesCanada, Germany
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 17, 2019
Enrollment StartFeb 13, 2019
Primary CompletionNov 5, 2019
Study CompletionNov 19, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.0 years ago

Interventions

RIST4721drug

RIST4721 oral solution

Placebodrug

Placebo oral solution